Hyper-CVAD Plus Ponatinib May Be Effective for Newly Diagnosed Ph+ Acute Leukemia

Share this content:
Combination of chemotherapy with ponatinib is effective in achieving early sustained remissions in newly diagnosed acute lymphoblastic leukemia.
Combination of chemotherapy with ponatinib is effective in achieving early sustained remissions in newly diagnosed acute lymphoblastic leukemia.

The combination of chemotherapy with ponatinib is effective in achieving early sustained remissions in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), results from an ongoing trial published online ahead of print in the journal The Lancet Oncology have shown.1

Because the combination of chemotherapy with a tyrosine kinase inhibitor has been shown to be an effective treatment for Ph+ ALL, researchers sought to evaluate the activity and safety of combining chemotherapy with ponatinib, a more potent BCR-ABL1 inhibitor than all other tyrosine kinase inhibitors, for patients with Ph+ ALL.

For the study, researchers enrolled 37 adult patients with Ph+ ALL who had not previously received treatment or had received fewer than 2 courses of previous chemotherapy with or without tyrosine kinase inhibitors.

All participants received 8 cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) alternating with high-dose methotrexate and cytarabine every 21 days. All patients also received ponatinib 45 mg daily for the first 14 days of cycle 1 then continuously during subsequent cycles.

Patients who achieved complete remission then received maintenance therapy with ponatinib 45 mg daily plus vincristine and prednisone monthly for 2 years followed by ponatinib indefinitely.

Results showed that 2-year event-free survival rate was 81% (95% CI: 64-90).

RELATED: Busulfan Plus Fludarabine Effective Preparative Regimen for HSCT in Acute Leukemia

In regard to safety, the most frequent grade 3 or higher treatment-related adverse events were infections during induction, elevated aspartate aminotransferase and alanine aminotransferase concentration, thrombotic events, myocardial infarction, hypertension, rash, and pancreatitis. Three patients died potentially related to treatment.

“New strategies, including dosing titration of ponatinib and optimized control of vascular risk factors, might further improve outcomes,” the authors concluded.

Reference

  1. Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study [published online ahead of print September 29, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00207-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters